Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer · Published 2026-08-04 · DOI 10.1002/ijc.70617

Free full text

Authors (10)

Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wang, J., Qi, P., Li, J., et al. (2026). Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study. International Journal of Cancer. https://doi.org/10.1002/ijc.70617

Related articles

• Helicobacter pylori Infection and the Risk of Biliary Tract and Pancreatic Cancers: Subsite‐Specific Associations in a Japanese Population · International Journal of Cancer · 2026 · Same journal
• Sodium‐Glucose Cotransporter 2 Inhibitors and Cancer Risk in Patients With Type 2 Diabetes Mellitus: An Active Comparator, New‐User Cohort Study · International Journal of Cancer · 2026 · Same journal
• Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma · International Journal of Cancer · 2026 · Same journal
• The Optimal Lung Cancer Ct Screening Strategy: A Cost‐Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions · International Journal of Cancer · 2026 · Same journal
• The Circulating Cholangiocarcinoma Protein Biomarkers CRP and MASP2 Also Predict Gallbladder Cancer Risk · International Journal of Cancer · 2026 · Same journal
• Obesity‐Driven Early‐Onset Colorectal Cancer: Mechanistic Insights and Emerging Clinical Implications · International Journal of Cancer · 2026 · Same journal
• Changing the History of Science—An Editorial Perspective on Critical Developments in Current Citation Practice, “Forgetting” the Pioneers of Scientific Discoveries · International Journal of Cancer · 2026 · Same journal
• Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety · International Journal of Cancer · 2026 · Same journal
• Neoadjuvant Chemotherapy Versus Upfront Surgery for cT2N1 or cT3a ‐ bN0 ‐1 Middle‐High Rectal Cancer · International Journal of Cancer · 2026 · Same journal
• HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer · International Journal of Cancer · 2026 · Same journal